Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H13NO8S2.2Na.H2O |
Molecular Weight | 499.423 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Na+].[Na+].[O-]S(=O)(=O)OC1=CC=C(C=C1)C(C2=CC=C(OS([O-])(=O)=O)C=C2)C3=CC=CC=N3
InChI
InChIKey=FHYUVJHZGPGDSP-UHFFFAOYSA-L
InChI=1S/C18H15NO8S2.2Na.H2O/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25;;;/h1-12,18H,(H,20,21,22)(H,23,24,25);;;1H2/q;2*+1;/p-2
Molecular Formula | C18H14NO8S2 |
Molecular Weight | 436.436 |
Charge | -1 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | HO |
Molecular Weight | 17.0073 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Picosulfuric acid (as sodium picosulfate) is a contact laxative, which is used in combination with: magnesium oxide, and anhydrous citric acid for cleansing of the colon as a preparation for colonoscopy in adults. Sodium picosulfate is a prodrug. It has no significant direct physiological effect on the intestine. But it is hydrolyzed by colonic bacteria to form an active metabolite: bis-(p-hydroxy-phenyl)-pyridyl-2-methane, BHPM, which acts directly on the colonic mucosa to stimulate colonic peristalsis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: colonic mucosa |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PREPOPIK Approved UsePREPOPIK (sodium picosulfate, magnesium oxide and anhydrous citric acid) for oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults. Launch Date2012 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
2.3 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIHYDROXYDIPHENYL-PYRIDYL METHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
21.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
209 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
275 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
7.4 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIHYDROXYDIPHENYL-PYRIDYL METHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
10 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21697613/ |
10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DEACETYLBISACODYL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
PubMed
Title | Date | PubMed |
---|---|---|
Analytical control of a pharmaceutical formulation of sodium picosulfate by capillary zone electrophoresis. | 2001 Feb 10 |
|
Investigation of the effects of YM-31636, a novel 5-HT3 receptor agonist, on defecation in normal and constipated ferrets. | 2001 Jul 20 |
|
Retrospective study of long-term treatment with sodium picosulfate. | 2004 Apr |
|
Sodium picosulfate in opioid-induced constipation: results of an open-label, prospective, dose-ranging study. | 2006 Jun |
|
Is bowel preparation required before cystoplasty in children? | 2006 Oct |
|
Interaction between Shaoyao-Gancao-Tang and a laxative with respect to alteration of paeoniflorin metabolism by intestinal bacteria in rats. | 2007 Aug |
|
Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. | 2007 Dec 3 |
|
Randomized clinical trial comparing sodium picosulfate with mannitol on the preparation FOR colonoscopy in hospitalized patients. | 2007 Jul-Sep |
|
OTC laxative use of sodium picosulfate â results of a pharmacy-based patient survey (cohort study). | 2008 Feb |
|
Commonly used bowel preparations have significant and different effects upon cell proliferation in the colon: a pilot study. | 2008 Nov 14 |
|
Changes of intestinal mucosal and plasma PYY in a diarrhea model rat and influence of loperamide as the treatment agent for diarrhea. | 2008 Sep |
|
Comparison of two common outpatient preparations for colonoscopy in children and youth. | 2009 |
|
Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. | 2010 Apr |
|
A review of laxative therapies for treatment of chronic constipation in older adults. | 2010 Dec |
|
Laxative activities of Mareya micrantha (Benth.) Müll. Arg. (Euphorbiaceae) leaf aqueous extract in rats. | 2010 Feb 16 |
|
Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation. | 2010 Sep |
Sample Use Guides
PREPOPIK ((sodium picosulfate, magnesium oxide, and anhydrous citric acid), supplied as a powder, must be reconstituted with cold water right before its use. There are two dosing regimens, each requires two separate dosing times: The preferred method is the “Split Dose” method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy. The alternative method is the “Day Before” method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy). Additional fluids must be consumed after every dose in both dosing regimens. Instruct patients to consume only clear liquids (no solid food or milk) on the day before the colonoscopy up until 2 hours before the time of the colonoscopy. Instruct patients that if they experience severe bloating, distention, or abdominal pain following the first dose, delay the second dose until their symptoms resolve.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1507649
Sodium picosulfate was biotransformed by intestinal flora that produced a novel sulfotransferase (not sulfatase). The biotransformation was activated by adding phenolic compounds such as phenol, acetaminophen and flavonoids. The enzyme activity related to this biotransformation was the highest in the contents of the caecum region of the intestine. The enzyme activity was 3.0 umole/hr/g wet feces in humans and 0.75 in rats (pH 8.0). The optimal pH was 9.0. The sulfotransferase activity was assayed in reaction mixture consisting of 60 uL of 50 mM PNS (occasionally sodium picosulfate), tyramine and 0.2 ml of the enzyme solution. Sulfatase activity was measured under the assay conditions for he sulfotransferase acitivity without the addition of the acceptor tyramine.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:25:26 GMT 2023
by
admin
on
Fri Dec 15 15:25:26 GMT 2023
|
Record UNII |
LR57574HN8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29697
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
||
|
WHO-VATC |
QA06AB58
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
||
|
WHO-ATC |
A06AB08
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
||
|
WHO-ATC |
A06AB58
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
||
|
WHO-VATC |
QA06AB08
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT001830
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | |||
|
LR57574HN8
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | |||
|
5282431
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | |||
|
C73845
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | |||
|
1614578
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | |||
|
DTXSID70156700
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | |||
|
SODIUM PICOSULFATE
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | |||
|
Sodium Picosulfate
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | |||
|
SUB10569MIG
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | |||
|
33688
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | RxNorm | ||
|
C005701
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | |||
|
4779
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | |||
|
SUB30654
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | |||
|
1307301-38-7
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | |||
|
CHEMBL1741134
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY | |||
|
LR57574HN8
Created by
admin on Fri Dec 15 15:25:26 GMT 2023 , Edited by admin on Fri Dec 15 15:25:26 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |